Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality worldwide, disproportionately affecting individuals in hard-to-reach communities. The introduction of the Cardisio AI test represents a transformative step in bridging healthcare inequalities by offering an accessible, community-based diagnostic tool for early detection of asymptomatic cardiovascular diseases.
Empowering Communities Through Technology
The Cardisio test employs cutting-edge technology that interprets three-dimensional vectorcardiography activity using a cloud-based artificial intelligence algorithm. This innovative approach allows for the identification of potential CVD in asymptomatic individuals, without the need for hospital visits, thereby reaching those who may face barriers to traditional healthcare access.
Study Design and Methodology
This prospective cohort study was conducted across diverse community settings, including general practices, pharmacies, and community health centres. Participants were asymptomatic adults aged 18 years and above, identified as having a QRISK3 score of ≥10% or other CVD risk factors. The study aimed to determine the efficacy of the Cardisio test in a real-world setting.
Participants underwent a simple 10-minute test involving the placement of five electrodes. The test results were classified into red, amber, or green, based on perfusion, structure, and arrhythmia parameters, which were then reviewed by a consultant cardiologist to determine the need for further clinical action.
Key Findings
Out of 628 tests conducted, 54% exhibited at least one amber or red result, indicating potential CVD. The Cardisio test demonstrated a positive predictive value of 80% and a negative predictive value of 90.4%. The strong association between red test results and the need for referral to cardiology clinics highlights the test's potential to facilitate timely and appropriate medical intervention.
Moreover, the study reported high participant satisfaction, with 88% recommending the test to others, underscoring its acceptability and ease of use within community settings.
Addressing Health Inequities
The Cardisio AI test aligns with NHS England's Core20PLUS5 initiative, which aims to reduce healthcare inequalities. By providing a reliable, near-patient diagnostic tool, the Cardisio test empowers primary care practitioners to make informed decisions, potentially reducing unnecessary hospital referrals and supporting the early detection of CVD in high-risk populations.
Conclusion and Future Implications
This study underscores the potential of the Cardisio AI test to revolutionise CVD screening practices by offering a community-centric approach that is both efficient and equitable. As healthcare systems strive to address the challenges of undiagnosed cardiovascular conditions, the integration of AI-based diagnostics could play a pivotal role in enhancing patient outcomes and reducing the burden on healthcare resources.
Future research should focus on expanding the test's application across more diverse populations and exploring its long-term impact on healthcare delivery and patient care. By continuing to harness the power of artificial intelligence, we can move closer to achieving a more inclusive and effective healthcare system for all.
Source: Community-based cardiovascular risk assessment using the CardisioTM AI test: